Secukinumab in psoriasis patients with concurrent psoriatic arthritis: Demographics and disease characteristics in the Corrona Psoriasis Registry - 11/08/17
Doi : 10.1016/j.jaad.2017.04.886
Le texte complet de cet article est disponible en PDF.
Alice B. Gottlieb, New York Medical College; Bruce Strober, University of Connecticut Health Center; April W. Armstrong, University of Southern California; Jeffrey D. Greenberg, Corrona LLC; Chitra Karki, Corrona LLC; Marc Mason, Corrona LLC; Isabelle Gilloteau, Novartis AG; Adriana Guana, Novartis; Mark Lebwohl, Icahn School of Medicine at Mount Sinai
Le texte complet de cet article est disponible en PDF.| Commercial support: This study is sponsored by Corrona, LLC. The Corrona Psoriasis Registry is funded by Novartis Pharmaceutical Corporation and Eli Lilly and Company. Corrona, LLC. has been supported through contracted subscriptions in the last two years by AbbVie and Amgen. |
© 2017
Publié par Elsevier Masson SAS.
Vol 76 - N° 6S1
P. AB227 - juin 2017 Retour au numéro
Article précédent
- Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis
- Secukinumab in psoriasis patients with concurrent psoriatic arthritis: Patient-reported outcomes in the Corrona Psoriasis Registry
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?